Filed by Millennium Chemicals Inc.
Pursuant to Rule 425 under the Securities Act of 1933 and
Deemed Filed Pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
Subject Company: Millennium Chemicals Inc.
Commission File No. 1-12091
Date: March 29, 2004
This filing contains slides used by Millennium in a presentation to senior leaders and employees on March 29, 2004. This information is being filed pursuant to Rule 425 under the Securities Act of 1933.
Millennium/Lyondell Announcement
Leadership Meeting March 29, 2004
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the benefits of the proposed transaction between Lyondell Chemical Company (Lyondell) and Millennium Chemicals Inc. (Millennium), including financial and operating results, the parties plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Lyondells and Millenniums respective managements and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements. The following factors, among others, could affect the proposed transaction and the anticipated results: approval by Lyondells and Millenniums respective shareholders, amendments to Lyondells and Millenniums respective credit facilities, the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Act, the receipt of other competition law clearances and the parties ability to achieve expected synergies in the transaction within the expected timeframes or at all. Additional factors that could cause Lyondells results to differ materially from those described in the forward-looking statements can be found in Lyondells Annual Report on Form 10-K for the year ended December 31, 2003, which was filed with the Securities and Exchange Commission (the SEC) on March 12, 2004. Additional factors that could cause Millenniums results to differ materially from those described in the forward-looking statements can be found in Exhibit 99.1 to Millenniums Annual Report on Form 10-K for the year ended December 31, 2003, which was filed with the SEC on March 12, 2004 (the Millennium 10-K).
Lyondell and Millennium will file a joint proxy statement/prospectus with the SEC in connection with the proposed transaction. Investors and security holders are urged to read that document, when it becomes available, because it will contain important information. Investors and security holders may obtain a free copy of that document (when it becomes available) and other documents filed by Lyondell and Millennium with the SEC at the SECs web site at www.sec.gov. The joint proxy statement/prospectus (when it becomes available) and the other documents filed by Lyondell may also be obtained free from Lyondell by calling Lyondells Investor Relations department at (713) 309-4590 and may be obtained free from Millennium by calling Millenniums Investor Relations department at (410) 229-8113.
The respective executive officers and directors of Lyondell and Millennium and other persons may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Lyondells executive officers and directors is available in its proxy statement filed with the SEC by Lyondell on March 16, 2004, and information regarding Millenniums directors and its executive officers is available in the Millennium 10-K. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC.
Page 2
What is being announced
Millennium will combine with Lyondell in a stock-for-stock transaction
Creates the third largest independent publicly traded chemical company in North America
- Leading integrated commodity and intermediates chemical businesses with leadership positions across range of market segments
Combined revenues of over $11 billion
Combined market cap of nearly $4 billion
Page 3
Significant Market Positions
1st Propylene oxide and styrene monomer globally
2nd Ethylene and propylene in North America
2nd TiO2 globally
2nd Acetic acid and VAM in North America
3rd Polyethylene in North America
58.75% stake in largest extra heavy crude refinery in North America
Page 4
Combined 2003 Sales
Millennium Total Sales $3.6 B
Equistar 52%
TiO2 33%
Specialty Chemical 3%
Acetyls 12%
Lyondell Total Sales $10.9 B
IC&D 35%
LCR 23%
Equistar 42%
Equistar 52%
IC&D 33%
TiO2 10%
Acetyls 4%
Specialty Chemical 1%
Total Combined Sales $11.4 B
(excluding proportionate share of LCR)
Page 5
Rationale for the merger
Key benefits
Greater diversity better enables weathering of economic and industry cycles
Increased global footprint
Simplified ownership of Equistar, enhancing ability for future opportunities in the chemical industry
Greater scale provides greater access to capital and other resources
Opportunity for operational synergies
Page 6
What it means to Millennium
For Investors
Meaningful premium in stock price over current value
Full advantage of upturn in ethylene cycle
Diversity from more stable cash flow businesses
Improved liquidity on a combined basis
Simplified Equistar ownership, enhancing ability for future opportunities in the chemical industry
Significant institutional overlap
Increased market cap may attract new stockholders
Attractive dividend
Page 7
Combined Debt and Liquidity Management
Total Debt
($ in U.S. millions)
Lyondell Millennium
At 12/31/03 Combined (a)
Debt 7932 2150
Cash 846 268
Net Debt 7086 1882
Market Equity (approx) 4000 800
Total Market Capitalization 11086 2682
Net Debt / Total Capitalization 64% 70%
(a) including share of Equistar
Total Liquidity
($ in U.S. millions) $1709
A/R Facilities $163
Undrawn Portion of Revolvers $700
Cash $846
December 2003
Increases financial flexibility with improved leverage and increased liquidity
Page 8
What it means to Millennium
For Employees
Be a part of a larger scale company sharing same philosophy towards Operational Excellence
TiO2 business will continue to be operated out of Baltimore, requiring both business and support services
Acetyls to be integrated with Equistar and managed from Houston
Will minimize reductions through attrition, hiring freeze where at all possible
Page 9
What it means to Millennium
For Customers
Lyondell has a strong commitment to Millenniums core businesses and customers
Operational Excellence Model in both companies -committed to a competitive cost profile globally
Proven expertise with technology advancements
For Communities
Both companies strongly promote responsible safety, health and environmental principles and practices
Top tier safety performance
Page 10
How company will be structured
During transition period, no change to existing leadership or organizational structure
Combined company will be named Lyondell
Dan Smith will continue as CEO upon merger
Reporting structures not yet determined
Page 11
Expected timing
Expect transaction will be completed in the third quarter of 2004
Requires shareholder approval of both companies
Requires regulatory approval
Page 12
Next Steps
Joint Press Release issued before market opened today
Letter from REL sent out at 9:00 A.M. to all employees
Joint Analyst Meeting in NYC at 12 noon today-Webcast available
Key customers, suppliers will be contacted today
Leaders to notify employees in respective groups -Powerpoint, Q&As sent out this AM
Dan Smith to visit Hunt Valley, RCB on Tuesday
Page 13